The landscape of pharmacological interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, compounds like Reta, demonstrating impressive glucose https://henrijbyx642128.canariblogs.com/glp-3-receptor-agonists-reta-trizepatide-and-beyond-53724128